Vortioxetine is a prescription antidepressant approved for adult major depression. Its clearest value is treating depression and lowering relapse risk, though most evidence comes from its makers and independent reviewers judged its quality low. Manufacturer-funded trials support faster thinking during depression; results outside it are mixed. Main costs are early nausea, dose-related sexual dysfunction, and low-sodium, bleeding and drug-combination warnings. Its brain-sharpening value in healthy aging remains unproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum sodium | 135–145 mmol/L | Detects drug-induced low blood sodium |
| PHQ-9 score | Below 5 | Tracks depressive symptoms |
| DSST score | No established target; change from the individual's own baseline | Processing speed |
| CYP2D6 genotype | No established target; metabolizer status recorded | Poor metabolizers limited to 10 mg |
| INR | Not specified in the ER | Clotting check in people on warfarin |
| Serum osmolality | Not specified in the ER | Blood concentration check when sodium is low |
Cadence: Symptom questionnaires at 2, 4 and 8 weeks, then every 3 months; sodium at baseline and 2–4 weeks in adults over 65 or on diuretics, and again after dose increases; processing-speed test at 8 weeks and every 6–12 months; sexual-function review at each visit; INR with warfarin when vortioxetine is started, dose-adjusted or stopped